• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体神经内分泌肿瘤中的染色体改变模式:侵袭性肿瘤中的大量缺失。

Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors.

作者信息

Jentus Maaia Margo, Bakker Leontine, Verstegen Marco, Pelsma Iris, van Wezel Tom, Ruano Dina, Kapiteijn Ellen, Crobach Stijn, Biermasz Nienke, Morreau Hans

出版信息

Endocr Relat Cancer. 2024 Dec 19;32(1). doi: 10.1530/ERC-24-0070. Print 2025 Jan 1.

DOI:10.1530/ERC-24-0070
PMID:39441837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11729050/
Abstract

The molecular biology of pituitary neuroendocrine tumors (PitNETs) revealed few recurrent mutations and extensive chromosomal alterations, with the latter being the driving force in a subset of these lesions. Addressing the need for an easily applicable diagnostic tool, we conducted a retrospective study of 61 PitNETs operated at a tertiary care center. All cases were subtyped according to the 2022 WHO Classification of Endocrine Tumors. A genome-wide next-generation sequencing panel targeting 1500 single nucleotide polymorphisms (SNPs) was used to classify chromosomal imbalances, loss of heterozygosity, and copy number variations in DNA from formalin-fixed paraffin-embedded tissues. We identified four distinct chromosomal patterns, with varying distribution among different tumor lineages. Forty-two of 61 (69%) PitNETs showed chromosomal alterations. Gonadotroph PitNETs showed mostly quiet genomes. The majority of lactotroph PitNETs (19/20, 95%) were altered, exhibiting a gained genome and a remarkably low recurrence rate. Nine of ten (90%) corticotroph PitNETs harbored chromosomal alterations, of which two aggressive corticotroph tumors and one metastatic corticotroph PitNET showed massive chromosomal losses, leading to near-haploid/near-homozygous genomes. The comparison of the molecular profile of primary and recurrent PitNETs of five patients showed no significant accumulation of alterations over time. A simple genome-wide 1500-SNP test can be used in the identification of outspoken aggressive subsets of PitNETs by the occurrence of a near-haploid/near-homozygous genome. Furthermore, the presence of neoplastic tissue in the resected material can be potentially confirmed for non-gonadotroph PitNETs under suboptimal histological assessment conditions.

摘要

垂体神经内分泌肿瘤(PitNETs)的分子生物学研究显示,复发性突变较少,染色体改变广泛,后者是这些病变中一部分的驱动因素。为满足对易于应用的诊断工具的需求,我们对一家三级医疗中心手术的61例PitNETs进行了回顾性研究。所有病例均根据2022年世界卫生组织内分泌肿瘤分类进行亚型分类。使用靶向1500个单核苷酸多态性(SNP)的全基因组下一代测序面板对福尔马林固定石蜡包埋组织中的DNA进行染色体不平衡、杂合性缺失和拷贝数变异分类。我们确定了四种不同的染色体模式,在不同肿瘤谱系中的分布各不相同。61例(69%)PitNETs中有42例显示染色体改变。促性腺激素细胞PitNETs的基因组大多较为稳定。大多数催乳素细胞PitNETs(19/20,95%)发生改变,表现为基因组增加且复发率极低。10例促肾上腺皮质激素细胞PitNETs中有9例(90%)存在染色体改变,其中2例侵袭性促肾上腺皮质激素肿瘤和1例转移性促肾上腺皮质激素细胞PitNET显示大量染色体丢失,导致近乎单倍体/近乎纯合基因组。对5例患者的原发性和复发性PitNETs的分子特征进行比较,结果显示随着时间推移,改变没有显著累积。一种简单的全基因组1500-SNP检测可用于通过近乎单倍体/近乎纯合基因组的出现来识别明显侵袭性的PitNETs亚组。此外,在组织学评估不理想的情况下,对于非促性腺激素细胞PitNETs,可潜在地确认切除材料中存在肿瘤组织。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/9d71faeece2b/ERC-24-0070fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/d42207026059/ERC-24-0070fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/7c919cb7b50b/ERC-24-0070fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/9d71faeece2b/ERC-24-0070fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/d42207026059/ERC-24-0070fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/7c919cb7b50b/ERC-24-0070fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5809/11729050/9d71faeece2b/ERC-24-0070fig3.jpg

相似文献

1
Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors.垂体神经内分泌肿瘤中的染色体改变模式:侵袭性肿瘤中的大量缺失。
Endocr Relat Cancer. 2024 Dec 19;32(1). doi: 10.1530/ERC-24-0070. Print 2025 Jan 1.
2
Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.染色体不稳定性在垂体神经内分泌肿瘤预后预测中的作用。
Acta Neuropathol Commun. 2020 Nov 10;8(1):190. doi: 10.1186/s40478-020-01067-5.
3
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.全基因组杂合性缺失预测垂体神经内分泌肿瘤侵袭性和治疗抵抗行为。
Acta Neuropathol. 2024 May 17;147(1):85. doi: 10.1007/s00401-024-02736-8.
4
Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.同步发生的不同细胞谱系的垂体神经内分泌肿瘤。
Endocr Pathol. 2018 Dec;29(4):332-338. doi: 10.1007/s12022-018-9545-4.
5
Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.全基因组甲基化谱分析可区分良性、侵袭性和转移性垂体神经内分泌肿瘤。
Acta Neuropathol. 2024 Nov 23;148(1):68. doi: 10.1007/s00401-024-02836-5.
6
Pangenomic Classification of Pituitary Neuroendocrine Tumors.基于泛基因组的垂体神经内分泌肿瘤分类。
Cancer Cell. 2020 Jan 13;37(1):123-134.e5. doi: 10.1016/j.ccell.2019.11.002. Epub 2019 Dec 26.
7
Comprehensive Classification of Surgically Resected Pituitary Neuroendocrine Tumors: Updates From a Single-Institution Experience Based on the WHO 5th Edition.手术切除垂体神经内分泌肿瘤的综合分类:基于世界卫生组织第5版的单机构经验更新
J Korean Med Sci. 2025 Apr 28;40(16):e56. doi: 10.3346/jkms.2025.40.e56.
8
Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.CDKN2A 缺失在高危垂体神经内分泌肿瘤中的频率和作用。
Endocr Pathol. 2020 Jun;31(2):166-173. doi: 10.1007/s12022-020-09609-2.
9
DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.肿瘤抑制基因在垂体神经内分泌肿瘤中的甲基化。
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1272-1282. doi: 10.1210/jc.2018-01856.
10
High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience.垂体神经内分泌肿瘤(PitNENs)的高级别进展、肉瘤样转化和/或转移:加州大学旧金山分校的经验
Endocr Pathol. 2024 Dec;35(4):338-348. doi: 10.1007/s12022-024-09829-w. Epub 2024 Oct 10.

引用本文的文献

1
Differential expression of PTEN, pAKT1, pRPS6, and mismatch repair proteins in pituitary neuroendocrine tumors.PTEN、pAKT1、pRPS6和错配修复蛋白在垂体神经内分泌肿瘤中的差异表达
Virchows Arch. 2025 Jul 16. doi: 10.1007/s00428-025-04176-5.

本文引用的文献

1
Pituitary carcinoma: reclassification and implications in the NET schema.垂体癌:在神经内分泌肿瘤分类体系中的重新分类及意义
Endocr Oncol. 2022 Mar 30;2(1):R14-R23. doi: 10.1530/EO-22-0041. eCollection 2022 Jan.
2
A clinically applicable molecular classification of oncocytic cell thyroid nodules.一种临床适用的嗜酸细胞性甲状腺结节的分子分类。
Endocr Relat Cancer. 2023 Aug 3;30(9). doi: 10.1530/ERC-23-0047. Print 2023 Sep 1.
3
Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.表达 PIT1 和 SF1 的多谱系垂体神经内分泌肿瘤(PitNETs)。
Endocr Pathol. 2023 Sep;34(3):273-278. doi: 10.1007/s12022-023-09777-x. Epub 2023 Jun 2.
4
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.世界卫生组织垂体神经内分泌肿瘤分类:临床病理评估。
Endocr Relat Cancer. 2023 Jun 22;30(8). doi: 10.1530/ERC-23-0021. Print 2023 Aug 1.
5
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.真实世界中免疫治疗对垂体瘤的疗效和预测因素:一项队列研究。
Eur J Endocrinol. 2022 Oct 17;187(5):685-696. doi: 10.1530/EJE-22-0647. Print 2022 Nov 1.
6
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.错配修复缺陷型侵袭性垂体腺瘤患者对免疫检查点抑制剂治疗的完全缓解:病例报告。
Neurosurgery. 2022 Aug 1;91(2):e51-e56. doi: 10.1227/neu.0000000000002024. Epub 2022 May 13.
7
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.垂体神经内分泌肿瘤:神经内分泌肿瘤分类的模型。
Mod Pathol. 2021 Sep;34(9):1634-1650. doi: 10.1038/s41379-021-00820-y. Epub 2021 May 21.
8
Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.垂体神经内分泌肿瘤的单细胞转录组和基因组分析。
Neuro Oncol. 2021 Nov 2;23(11):1859-1871. doi: 10.1093/neuonc/noab102.
9
USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.USP8 和 TP53 驱动因子与促肾上腺皮质激素腺瘤队列中的 CNV 相关,该队列中富集了侵袭性肿瘤。
J Clin Endocrinol Metab. 2021 Mar 8;106(3):826-842. doi: 10.1210/clinem/dgaa853.
10
Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.垂体腺瘤中端粒长度改变和 ATRX/DAXX 缺失。
Mod Pathol. 2020 Aug;33(8):1475-1481. doi: 10.1038/s41379-020-0523-2. Epub 2020 Mar 18.